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Abstract
Background: Angiogenesis is widely investigated in conjunction with cancer development, in particular because of
the possibility of early stage detection and of new therapeutic strategies. However, such studies are negatively
affected by the limitations of imaging techniques in the detection of microscopic blood vessels (diameter 3-5 μm)
grown under angiogenic stress. We report that synchrotron-based X-ray imaging techniques with very high spatial
resolution can overcome this obstacle, provided that suitable contrast agents are used.
Results: We tested different contrast agents based on gold nanoparticles (AuNPs) for the detection of cancer-
related angiogenesis by synchrotron microradiology, microtomography and high resolution X-ray microscopy.
Among them only bare-AuNPs in conjunction with heparin injection provided sufficient contrast to allow in vivo
detection of small capillary species (the smallest measured lumen diameters were 3-5 μm). The detected vessel
density was 3-7 times higher than with other nanoparticles. We also found that bare-AuNPs with heparin allows
detecting symptoms of local extravascular nanoparticle diffusion in tumor areas where capillary leakage appeared.
Conclusions: Although high-Z AuNPs are natural candidates as radiology contrast agents, their success is not
guaranteed, in particular when targeting very small blood vessels in tumor-related angiography. We found that
AuNPs injected with heparin produced the contrast level needed to reveal–for the first time by X-ray imaging–
tumor microvessels with 3-5 μm diameter as well as extravascular diffusion due to basal membrane defenestration.
These results open the interesting possibility of functional imaging of the tumor microvasculature, of its
development and organization, as well as of the effects of anti-angiogenic drugs.
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Background
Limited contrast has been a crucial problem in radiology
since the discovery of X-rays [1]. The problem is parti-
cularly acute in the imaging of small blood vessels [2],
in particular in the detection of vascular angiogenesis,
critical for the early diagnosis of cancer [3], notably for
tumors becoming malignant after vascularization.
This is a relevant issue: angiogenesis is widely investi-
gated in conjunction with cancer development [4-8],
and could lead to early detection and new therapeutic
strategies [9,10]. However, such studies are negatively
impacted by the limitations of established imaging tech-
niques in the detection of micro-vessels. New
approaches, synchrotron-based X-ray micro-radiology
and micro-tomography, were recently tested for angio-
graphy studies [2,3,11-13]. Effective contrast agents are
highly desirable for these techniques.
Finding such agents is therefore a prime objective, in
particular for nanotechnology. Nanoparticles and other
nanosystems are indeed increasingly investigated as con-
trast agents for radiology. However, the effectiveness of
different types of nanoparticles in angiogenesis studies
was not yet satisfactorily tested. Extensive tests are
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and convection of the agent in the vessels [14-17].
Nanoparticles consisting of high-Z elements are good
candidates as angiography contrast agents [7,18-20],
with or without surface modifications. Gold nanoparti-
cles are particularly interesting [21-27] for a number of
reasons including: the potentially good biocompatibility,
the ample possibilities for surface chemistry manipula-
tions and the recent discovery of new and powerful irra-
diation-based methods for the fabrication of dense,
stable, and mono-dispersed colloids [19,20,28,29].
These factors justified the present study. We obtained
very good results in vivo with bare-AuNPs in conjunc-
tion with heparin, specifically the detection of small (3-5
μm) blood vessels, whereas the tests were less positive
for AuNPs coated with mercaptoundecanoid acid
(MUA) [30] and for commercial (ExiTron
® Nano 6000)
colloidal nanoparticles [31].
We selected for our tests MUA since it is a widely
used coating agent, for example to control the nanopar-
ticle size. ExiTron nano 6000 is a commercial alkaline
earth metal-based contrast agent used for preclinical
computed tomography. We decided to study bare-
AuNPs both alone and in conjunction with heparin,
since this is as an anti-clotting and fluidizing agent, pre-
venting nanoparticle aggregation.
We preferred catheter-supported local injection rather
than intravenous injection since the latter is more effec-
tive for systemic imaging of large areas, whereas in our
case we targeted localized imaging–e.g., a sub-cutaneous
tumor–and a large nanoparticle concentration inside
local small vessels. As a noteworthy side result, poten-
tially interesting for the study of tumor angiogenesis
properties [4,9,32,33], bare-AuNPs with heparin also
revealed the diffusion of nanoparticles at leakage loca-
tions of the microvessels.
Results and discussion
The tests were performed with the aforementioned types
of AuNP contrast agents: MUA-coated, commercial col-
loidal and bare, alone or with heparin injection. For
each nanoparticle type, we performed two series of tests:
in vivo microradiological imaging in real time, followed
by high resolution X-ray microscopy imaging of fixed
specimen (10-30 μm slices) from the same animals. The
first tests probed the capability to detect the smallest
vessels in vivo; the second analyzed in detail the nano-
particle spatial distribution. The imaging procedure
included in some cases tomographic reconstruction.
Figure 1 shows an overall performance comparison of
the different types of nanoparticles. The arrows mark
some of the small detectable vessels in the in vivo
images: (a) 20 μm diameter for MUA-coated AuNPs, (b)
88 μm for commercial ExiTron
® Nano 6000, (c) 15 μm
for bare-AuNPs and (d) 6 μm for bare-AuNPs plus
heparin injection. It is qualitatively clear that the ulti-
mate detectable vessel size changes significantly from
one particle type to another.
The first part of our study concerned MUA-coated
AuNPs with an average size ~4 nm. Potentially, such
nanoparticles have good physical characteristics for
high-resolution imaging: small but mono-dispersed size
and good colloidal stability. The tests, however, were
only partially satisfactory.
On one hand, Figure 2a and 2b show that MUA-
coated AuNPs can be imaged in vivo and in real time
(Additional file 1: Figure S1) to delineate the major
microvasculature and microvessels down to < 20 μmi n
diameter (inset of Figure 2a). We detected no particle
aggregation, which could oth e r w i s ea f f e c tt h ef l o wa n d
filling of very small microvessels and the microvascula-
ture perfusion–that is also visible in the tumor part of
the tissue. On the other hand, most parts of the micro-
vasculature, including those expected in normal areas,
are missing from these images.
We used high-resolution microscopy to check, both
for the normal and cancer regions, if the MUA-coated
AuNPs remained in the capillaries or diffused out of
t h e m .T h er e s u l t ,s h o w ni nF i g u r e2 ca n d2 d ,w a st h a t
Figure 1 Direct comparison of the performances of the
different tested types of AuNPs in imaging very small vessels.
in vivo X-ray micrographs taken in the leg region with (a) MUA-
coated AuNPs, (b) commercial ExiTron
® Nano 6000, (c) bare-AuNPs
and (d) bare-AuNPs with heparin. All images in our study were
taken immediately after the corresponding injections. The arrows
mark the smallest observable vessels: the measured diameters are
20 μm in (a), 88 in (b), 15 in (c) and 6 in (d). The scale bar of Figure
1b, 200 μm, is valid for all four panels
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tissues (Figure 2c), but leaked out of the anomalous
capillaries of cancer regions (Figure 2d).
It is also qualitatively clear that the lowest vessel dia-
meters in the well-ordered microvasculature of normal
tissues (Figure 2c) are substantially smaller than those
detectable in Figure 2a and 2b. Likewise, Figure 2d
shows very small vessels in a tumor area (marked by the
arrowhead), whereas no vessel smaller than tens of μm
c a nb ed e t e c t e di nt h et u m o ra r e ai nF i g u r e2 aa n d2 b .
This difference can be attributed to the relatively low
Au concentration of the MUA-AuNP colloid that does
not provide sufficient contrast for in vivo imaging (while
high resolution X-ray imaging of fixed specimen is not
affected by this problem). Whatever the cause, our
empirical conclusion is that this type of particles is not
suitable for in vivo detection of very small capillaries,
due to insufficient contrast.
As to the leakage of MUA-AuNP out of the microves-
sels as seen in Figure 2b and confirmed by Figure 2d,
we can argue that the nanoparticles size is large enough
to avoid free diffusion, but also small enough to diffuse
through the basal membrane apertures observed in
abnormal cancer capillaries. Most importantly, these
results directly reveal the leaking of nanoparticles out of
tumor microvessels, a proposed reason for the differen-
tial nanoparticle accumulation at tumor areas.
The second tested contrast agent was the commercial
product ExiTron
® Nano 6000 (average nanoparticle size
~110 nm), currently used for small-animal angiography.
The results were again rather negative: we could image
only vessels with diameter larger than 23 μm (Figure 3a-
3c). The high-resolution X-ray microscopy images (Fig-
ure 3d and 3e) showed that these nanoparticles were
indeed perfused into subcutaneous tumor and muscle
vessels. Therefore, the reason why this agent failed to
image the smallest vessels was again low contrast.
Furthermore, no extracellular diffusion was detected, as
expected for such large nanoparticles.
The third series of tests was conducted on bare-
AuNPs. These nanoparticles are known to be unstable
in blood: they agglomerate and obstruct vessels. Our
bare-AuNP colloids were prepared by reduction with
intense X-ray irradiation, which provides much better
colloidal stability in blood than the citrate reduction
method [28]. However, Figure 4a (the sequential images
are shown in Additional file 2: Figure S2) and the mag-
nified square area shown in 4b reveal that these AuNPs
are not completely immune from problems, particularly
in the blood stream inside microvessels, and do agglom-
erate forming clusters. High-resolution X-ray micro-
scopy images (Figure 4c and 4d) show that the vessels
are at least partially coated.
Tomographically reconstructed X-ray images (Figure
4e and Additional file 3: Figure S3, Additional file 4:
Video S1, Additional file 5: Video S2) confirm that the
bare-AuNPs adhere to the vessel wall while forming
clusters, eventually blocking the flux inside the vessels
(yellow arrowheads in Figure 4e). This behavior does
not allow imaging very small vessels and creates artifacts
for in vivo microangiography, due to aggregation and
obstruction. The detectable vessel size limit for fixed
specimens was approximately 8 μm, substantially better
than that of ExiTron, and the density of the revealed
microvessels was higher than for MUA-AuNP. The high
concentration of small (~20 nm) nanoparticles yielded
by our fabrication method may explain this better per-
formance, since it allows the nanoparticles to be per-
fused and to aggregate only in the microvessels.
To prevent the formation of large clusters and make it
possible to detect even smaller vessels, we injected bare-
AuNPs after perfusion of the anti-coagulant heparin.
The results were more positive than those of the other
tests. No large clusters were observed and the AuNPs
distributed through micro-vessels without obstruction,
Figure 2 X-ray micrographs of the microvasculature of the leg
area of a tumor bearing mouse taken after injection of MUA-
coated AuNP. In vivo snapshots like (a) were taken from a
sequence of microradiology images 5 min after the injection; the
vessel size marked by the arrow in the inset is ~10 μm. (b)
Magnified images of the dotted-line square portion of (a) showing a
region of extravascular diffusion of the contrast agent. The scale
bars are (a) 500 μm, (b) 250 μm, inset in (a) 50 μm. (c) and (d) are
high resolution X-ray microscopy images of MUA-coated AuNPs in
muscle and in tumor microvessels. Some microvessels with rather
small diameter, ~3 μm, are marked by arrowheads. Substantial
extravascular diffusion is found in tumor area. The scale bar in (c)
and (d) is 5 μm
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specimens.
Figure 5 shows that the AuNPs were indeed uniformly
distributed throughout the vessels of the tumor and nor-
mal leg tissues. Some agglomerations appeared in tumor
areas (marked by arrowheads in Figure 5b) without,
however, preventing the detection of very small vessels–
such as the one marked by the yellow arrows in Figure
5c and in the inset of Figure 5e. This limited agglomera-
tion is reasonable since the tortuous character and inho-
mogeneous diameter of tumor vessels can cause
aggregation and accumulation of our dense contrast
agent.
We also verified that there was no heparin-induced
modification of the vessels morphology that could other-
wise interfere with our image analysis. Note that our
bare-AuNPs (1.57 mg/ml concentration) are well dis-
persed in distilled water but immediately precipitate in
PBS. The addition of 500 U/ml of heparin in the PBS
eliminated the precipitation: the nanoparticles were as
well dispersed as in distilled water (Additional file 6:
Figure S4). However, we also performed tests with bare-
AuNPs pre-mixed with heparin and the results in
detecting small vessels were much less satisfactory due
to the dilution of the nanoparticle concentration in the
pre-mixed solution. Further tests (underway) are needed
to check if possible physiological effects of co-injected
heparin contributed to the enhanced vessel detection.
The success of bare-AuNPs with heparin illustrates
the importance of the trade-off between particle aggre-
gation–which enhances the X-ray contrast–and the uni-
form distribution required to image all details of the
tumor microvasculature. In essence, with heparin the
aggregation of bare-AuNPs was found to be limited
even in very fine vessels.
Figure 5 also shows that by using bare-AuNPs with
heparin we could observe important details of the
tumor micro-vasculature. Specifically, more capillaries
were detected in muscle tissues (Figure 5c, e and 5f)
near the cancer area than in the tumor subcutaneous
tissue (Figure 5b). In the late stages of subcutaneous
tumor development, we could also see the angiogenesis-
related formation of capillaries in the tumor center (Fig-
ure 5g). Such results provide useful information about
the dynamics of tumor development.
Tomography images (Additional file 7: Video S3)
further confirmed the positive results of the heparin
tests. They showed indeed that bare-AuNPs accumu-
lated in the tumor vessels. In high-resolution images,
the AuNPs coated the vessel wall and in some cases
Figure 3 X-ray micrographs of the microvasculature of the leg area of a tumor bearing mouse, taken with the ExiTron
® Nano 6000
contrast agent. (a) is an in vivo microradiology image taken 4 min after the agent injection. (b) and (c) are magnified images of the square
regions in (a) corresponding to a tumor area (b) and to a normal tissue area (c). Some small vessels of diameter ~23 μm are marked by the
arrowheads. (d) and (e) are high resolution X-ray images showing microvessels in subcutaneous tissue and muscle vessels The arrowheads mark
examples of the smallest vessels, ~20 μm in (d) and ~8 μm in (e). Scale bars: 1 mm (a), 500 μm (b and c) and 10 μm (d and e)
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Page 4 of 12Figure 4 (a) and (b) are in vivo X-ray micrographs of the microvasculature of the leg region of a mouse taken with bare-AuNPs.T h e
smallest detected microvessel has ~8.6 μm diameter, marked by the yellow arrowhead in the inset of (b). Note that the AuNP distribution in the
vessels is not continuous. The yellow arrows emphasize that the nanoparticles aggregated in the vessel into large clusters, eventually blocking
the flux. (c), (d) and (e) are high resolution X-ray images of vessels in subcutaneous tissue partially coated by bare-AuNPs. Yellow arrowheads
indicate agglomerated AuNPs, the white arrow marks an endothelial cell nucleus and the white arrowheads mark erythrocytes in the vessels.
Most of the bare-AuNPs adhere to vessel walls and do not interact with erythrocytes. The scale bars are (a) 500 μm, (b) 250 μm (inset 50 μm) (c)
and (d)1 0μm and (e) 2.5 μm
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Page 5 of 12Figure 5 X-ray micrographs showing the microvasculature of normal tissue and tumors at different time after the tumor inoculation,
taken with bare-AuNPs and heparin injection. (a) In vivo image of the lateral thigh, 7 days after inoculation. (b) and (c) magnified images of
the left square in (a), near the tumor area, and of the right square, corresponding to normal tissue area (medial thigh). The arrowheads in (a)
and (b) mark vessels showing AuNP agglomeration while the yellow arrows mark vessels of < 6 μm diameter. (d) In vivo image of the normal
lateral thigh. (e) and (f) magnified images the left and right squares in (d). The inset in the lower left corner of (e) is an additionally magnified
image of its small square and the yellow arrow marks a < 6 μm diameter vessel. (g) In vivo image of the lateral thigh, 16 days after inoculation.
(h) magnified image of the square in (g). (i) image of a 1 mm thick tissue removed from the thigh shown in (g). (j) Magnified image of the
rectangle in (i); the yellow arrowheads mark abnormal vessels, the white arrowheads a vessel with ~2 μm diameter and the yellow arrows areas
with diffusion of bare-AuNPs. Scale bars: (a), (d) and (g): 2 mm; (b), (c), (e), (f), and (i): 500 μm; inset of (e) and (h): 50 μm and (j): 10 μm
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tribution of bare-AuNPs delineated the vasculature (Fig-
ure 6), especially for abnormal vessel areas.
As shown in Figure 6 and Additional file 8: Figure S5
and Additional file 9: Video S4, we could also detect the
diffusion of AuNPs from tumor capillaries. Tumor ves-
sels presented a highly disorganized and tortuous vascu-
lar morphology with irregularly varying diameter along
their length. Numerous “open windows” (probably due
either to endothelial fenestrae or basal membrane
Figure 6 High resolution X-ray images of a 7 day tumor in a mouse after heparin treatment and bare-AuNP injection.( a), (b)a n d( d)
are images taken from subcutaneous tumor areas whereas (c) refers to a normal tissue region. The two arrows in (b) mark the normal vessels;
the arrowhead marks tumor vessels that show extravascular diffusion of the bare-AuNPs. (d) shows abnormal microvasculature, especially in the
two marked squares, with bare-AuNPs diffused out of the microvessles. Scale bars: 10 μm( a and b) and 25 μm( c and d)
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inter-endothelial tight junctions and other possible
causes), could be clearly imaged in the vicinity of diffu-
sion areas of bare-AuNPs (the black square area in Fig-
ure 6a and 6d). These are symptoms of extravascular
diffusion occurring in blood capillaries abnormally
formed due to the tumor angiogenic stress. Therefore,
images like those of Figure 6 can illustrate this effect in
three dimensions and allow the analysis of detailed fea-
tures. In contrast, normal muscle vessels presented no
symptoms suggesting extravascular AuNP diffusion,
indicating that the vessel walls were well organized (Fig-
ure 6c).
In summary, our tests demonstrate the importance of
the nanoparticle preparation procedure when the objec-
tive is to image in vivo all the details of micro-vascula-
ture, down to the smallest ones. Furthermore, they
indicate that the use of X-ray imaging for microvascula-
tures requires a close attention to chemical properties of
contrast agents. On the negative side, we found that
MUA-coated AuNPs, ExiTron
® Nano 6000 and bare-
AuNPs per se cannot lead to the detection of the smal-
lest capillaries. On the positive side, this detection was
made possible by the co-injection of bare-AuNPs with
heparin, preventing nanoparticle aggregation and poten-
tial obstruction of small blood vessels. This enabled us,
for the first time, to detect by X-ray imaging in vivo
capillaries with diameter substantially smaller than 10
μm.
We put our conclusions about the smallest detectable
vessels in vivo on quantitative ground. We used the ves-
sel contrast parameter defined as C = [(Imax-Imin)/(Imax
+Imin)]/R,w h e r eImax, Imin are the maximum and mini-
mum pixel values for a line crossing the vessel [34] and
R is the average noise level for the probed area. A vessel
is detectable as long as C is larger than a threshold
value. Empirically, we estimated this threshold to be 0.5-
1.5.
For in vivo imaging, the quantitative evaluations were
extracted from the following statistical sets. 25, 16, 17
and 19 vessels were measured on each mouse for bare-
AuNPs with heparin, bare-AuNPs alone, MUA-AuNPs
and the Exitron
®. Three mice were tested for each case.
We extracted from the images the average C-value
corresponding to each measured vessels size; the results
are shown in Figure 7. The behavior is generally linear
except for bare-AuNP with heparin above ≈30 μm. Line-
arity can be easily understood assuming, for simplicity,
cylindrically shaped vessels. The deviation for bare-
AuNPs with heparin can be explained assuming that for
large sizes such nanoparticles can flow smoothly
through the vessels, with less aggregation on the vessel
wall and a weaker contribution to the contrast.
From the plots of Figure 7 we can quantitatively assess
the minimum detectable size. Setting the threshold C-
value at 0.75, the smallest vessels visible with bare-
AuNPs plus heparin have a diameter ≈9 μm. With bare-
AuNPs the smallest diameter is 15.5 μm; with MUA-
AuNPs or ExiTron
®,i tb e c o m e s2 3μm. Slightly larger
detectability thresholds C =1a n dC = 1.5 correspond,
in the four cases, to minimum vessel diameters of 11.5,
20, 34 and 24.5 μm, and of 12.8, 29, 55 and 50 μm.
These results quantitatively confirm our qualitative
conclusions.
By best fitting the plots of Figure 7, we found that the
slope for bare-AuNPs with heparin is 6.8 times larger
than without heparin, and approximately 15 times larger
than for MUA-AuNPs and Exitron
®. The heparin-
induced large slope enabled us to detect more vessels in
a given area: 83 per mm
2 on the average, compared to
27, 28 and 13 for bare-AuNPs alone, MUA-AuNPs and
the Exitron AuNP contrast agent.
Similar conclusions can be drawn for the fixed sam-
ples: the slope for bare-AuNPs with heparin is 1.9, 2.2
and 5.8 times larger than for bare-AuNPs alone, MUA-
AuNPs and Exitron
®. However, since the contrast agent
can be drained out during the fixation process, the con-
trast-vessel size relation is no longer strictly linear. The
detected vessels per mm
2 were 2.38 × 10
3 for bare-
AuNPs with heparin and 0.39 × 10
3,1 . 0×1 0
3 and 0.43
×1 0
3 for the other three cases. One should note that
fixed samples are less vulnerable to radiation damage
and high contrast images can be obtained with long
acquisition times. It is even possible to perform three-
dimensional tomography reconstruction to allow very
accurate measurements of the vessel size.
Figure 7 Plots of the contrast C-parameter (defined in the text)
vs the vessel diameter extracted from in vivo images for the
different investigated cases. It is clear that bare-AuNPs with
heparin lead to the detection of smaller vessels than the other
AuNP species
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successful is not entirely clear, so that our result should
be considered as experimental evidence, to be further
investigated. At this point, we can suggest that the good
dispersion properties of MUA-coated AuNPs and Exi-
Tron
® nanoparticles allows them to diffuse in the blood
without aggregation. The absorption contrast is not suffi-
cient to cause easily detectable delineation of small blood
vessels. However, the relatively unstable bare-AuNPs
agglomerate and adhere selectively on the walls of small
vessels. These stationary high-contrast agglomerates pro-
duce much higher contrast than the diluted nanocolloids.
As a corollary result, we found that the co-injection of
bare-AuNPs and heparin also allowed the detection of
symptoms of the extracellular diffusion due to angiogen-
esis stress. This is an important result on its own since
it opens the way to detailed studies of the rheological
properties of tumor blood capillaries as well as the
determination of capillary fenestration or morphological
aberrations of vessel walls.
We note that comparable progress in pathologic vas-
cular detection was achieved by Fourier transform infra-
red (FTIR) imaging [35]. Combined with the present
progress in X-ray imaging, these two techniques signifi-
cantly enhance the capability to analyze small blood ves-
sels on a microscopic scale.
Conclusions
T h ef u t u r ea p p l i c a t i o n so ft h ea b o v eo p t i m a lc o n t r a s t -
enhancement method–bare-AuNPs with heparin–depend
to some extent on the feasibility of using synchrotron
sources for in vivo studies of large animals. There is ample
evidence that tests can be conducted on live animals, and
we detected no image changes as a consequence of radia-
tion effects (up to 5 s for taking the high-resolution
images). Therefore, we can conclude that angiography
with our most effective procedure is feasible in principle
for large live animals. Some experience also exists on the
use of synchrotron techniques for live patients, but any
conclusion in that sense would be premature at this stage.
Methods
Cell culture
EMT-6 cells were obtained from American Type Cul-
ture Collection (ATCC) and cultured at 37°C in humid-
ity air atmosphere with 5% CO2. EMT-6 cells were
incubated with Dulbecco’s Modified Eagle’sM e d i u m :
Nutrient Mixture F-12 (DMEM/F12)/10% fetal calf
serum (FCS) was used as growth medium. All mediums
were purchased from GIBCO
®.
Tumor development
1×1 0
7 EMT cells/ml in phosphate buffer saline (PBS)
50 μl were inoculated in the subcutaneous tissue of left
leg region for 7 days to develop subcutaneous tumors.
All the procedures involving animals were approved by
the Academia Sinica Institutional Animal Care and Uti-
lization Committee (AS IACUC), Approval Number:
Protocol #RMiPHYHY2010039. BALB/cByJNarl mice
were provided by National Laboratory Animal Center,
Taiwan. All mice were housed in individual ventilated
cages (five per cage) with wood chip bedding and kept
at 24 ± 2°C with a humidity of 40%-70% and a 12-hour
light/dark cycle. The subcutaneous tumor volume was
e s t i m a t e da sv=0 . 5×a×b
2,w h e r eaa n dba r et h e
smallest and the largest diameters. Tumor imaging was
started after about 7 days, when the tumors reached a
volume of 100 to 120 mm
3.
Contrast agents
For the different tests we used ~200 μl of different con-
trast agents: colloidal solutions of bare-AuNPs, MUA-
modified AuNPs and ExiTron
® Nano 6000 nanoparti-
cles. All colloids except ExiTron were synthesized with
the X-ray irradiation method described in Refs[12,18].
ExiTron
® nano 6000 (Viscover
®), was purchased from
Miltenyi Biotech GmbH (Berlin, Germany). The colloi-
dal concentrations and average mean hydrodynamic dia-
meter were: 15.76 mg/ml and 15.5 ± 5.1 nm for bare-
AuNPs, 31.52 mg/ml and 3.91 nm MUA-modified
AuNPs, and 160 mg/ml and 110 nm for ExiTron
® Nano
6000 nanoparticles.
We analyzed the nanoparticle concentration by induc-
tively coupled plasma optical emission spectrometry
(ICP-OES, Perkin Elmer Optima 2000 DV, Norwalk,
CT). A particle size analyzer (90 plus, Brookhaven
Instruments Corp., Long Island, USA) determined the
hydrodynamic diameter of the nanoparticles. We per-
formed TEM measurements in a JEOL JEM-2100F sys-
tem with a 4,096 × 4,096 CCD imaging system (Gatan,
UltraScan 4000) operated with an accelerating voltage of
200 kV. The specimens were prepared by placing a drop
of solution on a carbon-coated copper grid and dried at
40°C. We also confirmed the nanoparticle size by TEM
measurements, showing that the shapes were all
spherical.
PE-08 catheters (BB31695, Scientific Commodities,
Inc., I.D.: 0.2 mm, O.D.: 0.36 mm) were used to inject
the contrast agents. The catheter was placed under
anesthesia induced by intramuscular injection of 10 μl
of Zoletil 50 (50 mg/kg; Virbac Laboratories, Carros,
France) per mouse (weight ~20-25 g). For heparin treat-
ment, 20 μl of heparin 5000 U/ml were injected via the
tail vein before contrast agent injection. The anterior
tight skin was incised along a 1-cm
2 circle and after a
sharp dissection; the catheter was inserted into the
femoral artery and secured by a 6-0 nylon ligature. With
the mouse in the imaging position, one of the contrast
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mice were kept under anesthesia using 1% isoflurene in
oxygen.
Tissue slice preparation
Seven days after the tumor cell inoculation and after
sacrifice, the tumors were removed from the subcuta-
neous tissue and the lungs. The specimens were
immersed in 3.7% paraformaldehyde for 24 hr. After
fixation, the specimens were embedded in paraffin and
sliced. The specimens were stained by heavy metal
staining for X-ray imaging. The stained specimens were
washed by distilled water 3 times for 5 minutes, dehy-
drated by washing with increasing ethanol concentra-
tions, embedded in Embed-812 Resin (EMS, Hatfield,
PA).
X-ray imaging
Micro-radiology was first implemented with unmono-
chromatized (white) synchrotron X-rays emitted by the
01A beamline wavelength shifter of the National Syn-
chrotron Radiation Research Center (Taiwan) [36]. The
photon energy ranged from 4 keV to 30 keV with a
peak intensity at energy ~12 keV and the beam current
was kept constant at 300 mA with the top-up opera-
tion mode. To obtain 3 × 3 mm images, the X-rays
were first converted to visible light by a CdWO4 single
crystal scintillator and then captured by an optical
microscope with a CCD camera (model 211, Diagnos-
tic instruments, 1,600 × 1,200 pixels). To limit the risk
of damage, the radiation dose was reduced by > 100
times by attenuating the emitted X-ray beam with a
1 . 1m mo fs i l i c o n .T h ed o s ew a s3 3 . 9G yp e r1 0 0m s
for a specimen thickness of 1 cm placed before the
animal.
The exposure time was ~100 ms and the distance
between the sample and the scintillator was ~15 cm; a
2× lens in the optical microscope was used to obtain
the desired field of view. The size of each pixel in the
final image taken with the 2× lens was ~2.8 × 2.8 μm
2.
A simple background flattening image filter was used
for large area micro-radiology images such as those of
Figures 2(a) and 3(b), 3(a)-(c), 4(a), (b) and 5(a)-(j).
High-resolution images were taken on the 32-ID
transmission X-ray microscopy (TXM) beamline of the
Advanced Photon Source (APS) at the Argonne
National Laboratory. The full-field TXM uses a set of
capillary condensers that provide fitting illumination of
the object, having a numerical aperture matched to a set
of zone plate lens objectives. The condensers are ellipti-
cally shaped glass capillaries. The inner diameter of 0.9
mm was chosen to maximize the vertical acceptance of
the APS undulator beam at 65 m from the source. The
estimated monochromatic X-ray flux focused by the
condenser (after a Si (111) double crystal monochroma-
tor) was 2 × 10
11/s at 8 keV.
The high brightness of the APS and the optimized
condensers design yielded an excellent imaging through-
p u to f5 0m s / f r a m ew i t h~ 1×1 0
4 CCD counts per
pixel. The microscope system could also operate in the
Zernike phase contrast imaging mode with a gold Zer-
nike phase ring placed at the back focal plane of the
zone plate objective. This mode increases the contrast
for fine features in the hard X-ray spectral region
[37-40].
Additional material
Additional file 1: Figure S1. Sequential images of MUA-coated AuNPs
injected in the femur artery. Only large vasculature can be imaged. Top:
sequence of microradiology images of a mouse leg at different times
after injection of 200 μL 31.52 mg/ml of 2.18 ± 0.51 nm MUA-coated
AuNPs. Small vessels are not fully visible. Pictures (a)-(e) were taken at 1
min intervals starting 60 s after injection: Middle: the same images as in
the top row, after image processing with a background flattening filter.
The vessel in the magnified portion in (j) is ~10 μm. Bottom: magnified
images of the square area in (j). Scale bars: (a)-(j) 500 μm; (k)-(o) 250 μm;
(j) (magnified portion) 50 μm.
Additional file 2: Figure S2. Sequential images of bare-AuNPs injected
in the femur artery: agglomerations were clearly observed (Figure 3). The
images were taken after injection of 200 μL 15.76 mg/ml of 15.5 ± 5.1
nm bare-AuNPs in the leg. The interval between images is ~60 s. The
images (f)-(o) were processed with a background flattening filter. The
vessel in the magnified portion in (o) is ~8.6 μm (yellow arrowhead).
Yellow arrows indicate that the nanoparticles adhere to the vessel wall
while forming clusters, eventually leading to the complete blockage of
the flux inside the vessels. Scale bars: (a)-(e) 500 μm, (k)-(o) 250 μm, (o)
(magnified portion) 50 μm.
Additional file 3: Figure S3. High resolution images showing bare-
AuNPs accumulated in small vessels without heparin treatment. (a) and
(d) are projection images; (b) and (g) tomographically reconstructed
pictures; (c), (e), (f) and (i) are slices of reconstructed images. (h) is a
combination of reconstructed slice images. Bare-AuNPs accumulated in
small vessels can be seen in (a), (d) and (g). Most of the bare-AuNPs did
agglomerated–see (c), (e) and (i) (the white arrows points to
agglomerated nanoparticles)–and adhered to the vessel walls as seen in
(c) and (f) (the yellow arrowheads point to the nucleus of endothelial
cells). There are no interactions with erythrocytes (marked by white
arrowheads in (c), (e), (f) and (i)). Bare-AuNPs are also seen on the surface
of white blood cells (marked by yellow arrows in (h) and (i)). Scale bars:
2.5 μm.
Additional file 4: Video S1. Multi projection images of high-resolution
X-ray images of bare-AuNPs accumulated in vessels.
Additional file 5: Video S2. Reconstructed high-resolution images of
bare-AuNPs accumulated in vessels.
Additional file 6: Figure S4. Tests on bare-AuNPs in different solution.
Bare-AuNPs in PBS (1.576 mg/ml) precipitate in a short time (left). When
bare-AuNPs are added to PBS combined with heparin (1.576 mg/ml in
PBS with 500 U/ml heparin), the precipitation does not occur (middle).
For comparison, bare-AuNPs suspend well in distilled water (right, 1.576
mg/ml).
Additional file 7: Video S3. Tomographically reconstructed video of
bare-AuNPs with heparin treatment. The movie shows well-distributed
bare-AuNPs in vessels (Figure 4i).
Additional file 8: Figure S5. High-resolution projection images (left) and
tomographically reconstructed images (middle and right) of bare-AuNPs
with heparin treatment, taken in the cancer area (a)-(c) or in the
subcutaneous area (d)-(f). The images (a), (b) and (c) show the leaking of
Chien et al. Journal of Nanobiotechnology 2012, 10:10
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Page 10 of 12AuNPs outside the cancer vessel area, whereas those in (d), (e) and (f)
show them aggregated on the vessel walls. Scale bar: 2.5 μm.
Additional file 9: Video S4. High resolution X-ray projection images of
bare-AuNPs leaking in tumor vessels after heparin treatment (Figure 5d).
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